NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Ezra, the NY-based startup transforming early cancer screening using MRI, announced today it has added the Ezra Prostate MRI with IV Contrast to its suite ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
ANNAPOLIS, MD, UNITED STATES, March 5, 2026 /EINPresswire.com/ — RadSite™, a leading accreditation agency promoting safety and quality in imaging, will host a ...
(RTTNews) - GE Healthcare said Monday that the U.S. Food and Drug Administration approved Clariscan, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio ...
The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants. Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective ...
A two-sequence abbreviated MRI protocol using hepatobiliary phase imaging detected recurrent hepatocellular carcinoma after ...
A study of 2,149 pediatric MRI exams shows that multi-region protocols and contrast imaging lengthen scan time and that every ...
A twist on magnetic resonance imaging that does not require gadolinium contrast appears to be as effective as standard imaging at detecting prostate cancers, according to a new study in JAMA. Experts ...
Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results